Shannon Klinger - Moderna Chief Secretary
| MRNA Stock | USD 41.11 2.86 7.48% |
Executive
Shannon Klinger is Chief Secretary of Moderna
| Age | 53 |
| Address | 200 Technology Square, Cambridge, MA, United States, 02139 |
| Phone | 617 714 6500 |
| Web | https://www.modernatx.com |
Moderna Management Efficiency
The company has return on total asset (ROA) of (0.0955) % which means that it has lost $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1752) %, meaning that it created substantial loss on money invested by shareholders. Moderna's management efficiency ratios could be used to measure how well Moderna manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.24. The current year's Return On Capital Employed is expected to grow to -0.26. At present, Moderna's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 23.1 B, whereas Other Current Assets are forecasted to decline to about 462.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marco LLM | CureVac NV | N/A | |
| Manmohan Singh | Beam Therapeutics | N/A | |
| Stephanie Franklin | Vertex Pharmaceuticals | N/A | |
| Laurent Goux | Krystal Biotech | N/A | |
| Patrick Baumhof | CureVac NV | N/A | |
| JD Esq | Novavax | 53 | |
| Esq CPA | Ocean Biomedical | 59 | |
| Nina Devlin | Vertex Pharmaceuticals | N/A | |
| Candice Masse | Elevation Oncology | N/A | |
| Ram Kamineni | Krystal Biotech | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Jennifer McDonough | Krystal Biotech | N/A | |
| Susie CFA | Vertex Pharmaceuticals | N/A | |
| Elaine OHara | Novavax | 56 | |
| Linea Aspesi | Editas Medicine | 54 | |
| Kathryn CPA | Krystal Biotech | 43 | |
| Charlene JD | Editas Medicine | N/A | |
| Anna MBA | Ginkgo Bioworks Holdings | 34 | |
| Erika Trahan | Novavax | N/A | |
| Kevin CPA | Enveric Biosciences | 60 | |
| Slavica StevanovicHeck | CureVac NV | N/A | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0955 |
Moderna Leadership Team
Elected by the shareholders, the Moderna's board of directors comprises two types of representatives: Moderna inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Moderna. The board's role is to monitor Moderna's management team and ensure that shareholders' interests are well served. Moderna's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Moderna's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shannon Klinger, Chief Secretary | ||
| Brad Miller, Chief Officer | ||
| Melanie MBA, Chief Officer | ||
| James Mock, Chief Officer | ||
| Stephane Bancel, CEO Director | ||
| John Reynders, Chief Officer | ||
| Ruchi Jain, Principal Scientist | ||
| Dave Johnson, Chief Officer | ||
| Lavina CFA, Senior Relations | ||
| Melissa Moore, Chief Board | ||
| Noubar Afeyan, Independent CoFounder | ||
| Stephen MD, President | ||
| Shannon JD, Chief Secretary | ||
| Allison MD, Senior Development | ||
| Colleen Hussey, Senior Communications | ||
| Patrick Bergstedt, Senior Vaccines | ||
| Tracey Franklin, Chief Officer | ||
| Michelle Hall, Principal Chemistry | ||
| Phil White, Vice Management | ||
| Lori Panther, Infectious Development | ||
| Jerh Collins, Chief Officer | ||
| Juan Andres, Pres Expansion | ||
| Charbel MPH, Senior Science | ||
| MD FAAP, Senior Development |
Moderna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Moderna a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0955 | ||||
| Profit Margin | (0.44) % | ||||
| Operating Margin | (0.04) % | ||||
| Current Valuation | 10.31 B | ||||
| Shares Outstanding | 384.82 M | ||||
| Shares Owned By Insiders | 9.52 % | ||||
| Shares Owned By Institutions | 71.60 % | ||||
| Number Of Shares Shorted | 34.38 M | ||||
| Price To Earning | 6.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moderna. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.85) | Earnings Share (5.81) | Revenue Per Share 13.275 | Quarterly Revenue Growth 0.017 | Return On Assets (0.1) |
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.